Podcast: Cell Therapy Firm Stempeutics' CEO On Japan Partnerships, India Trials Regulation Changes

CEO of cell therapy firm Stempeutics BN Manohar speaks to Scrip about partnering with Japanese firms for India’s first allogenic cell therapy Stempeucel. Amid a tough funding environment, AI and new manufacturing tech will drive savings as the company pursues new indications and changes in Indian regulation on clinical trials could make the CGT journey easier, he says in the interview.